Futura Medical Entered into a License Agreement with Haleon to Commercialise MED3000 in the US
Shots:
- Futura to receive $4M up front, commercial & performance-driven sales milestones b/w $5M & $45M along with royalty on all sales of MED3000 by Haleon
- Haleon will be responsible for all investment & activities related to the launch & marketing of the product in the US. Futura will provide ongoing technical support for OTC product development & commercialization opportunities
- MED3000 was approved as the first pan-European clinically proven topical treatment for ED available OTC & is now available in Belgium & UK. The 2 P-III studies demonstrated that MED3000 presents an effective clinically proven treatment for ED with a rapid speed of onset and a favorable benefit versus risk profile ideally suited for an 'Over the Counter' classification
Ref: Futura Medical | Image: Futura Medical
Related News:- Alimera Acquires Rights from EyePoint Pharmaceuticals to Commercialise Yutiq in the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
